Revenue Model
Project-based
Capital Intensity
Medium
Actual EBITDA multiples can vary materially based on business size, growth, recurring revenue, margins, customer concentration, owner dependence, geography and other company-specific factors.
Overview
Contract research organisations (CROs) in the life sciences sector typically trade at 5×–10× EBITDA. Long-term drug development service agreements with pharmaceutical clients, regulatory submission expertise, and specialist therapeutic area capability support premium valuations. Global pharmaceutical R&D spend provides strong structural demand. Client R&D budget cyclicality and specialist talent shortage are the primary risk factors.
Key Value Drivers
- Long-term drug development service agreements
- Regulatory submission and clinical trial expertise
- Specialist therapeutic area capability
- Global pharmaceutical R&D demand
- Accreditation and GCP compliance
Key Risks
- Client R&D budget cyclicality
- Specialist talent shortage
- Regulatory approval timelines
- Trial failure impacting revenue
- Competition from large global CROs